Iota-Carrageenan is a potent inhibitor of rhinovirus infection

被引:160
作者
Grassauer, Andreas [1 ,2 ]
Weinmuellner, Regina [1 ]
Meier, Christiane [1 ,2 ]
Pretsch, Alexander [1 ,2 ]
Prieschl-Grassauer, Eva [1 ,2 ]
Unger, Hermann [2 ]
机构
[1] Marinomed Biotechnol GmbH, A-1210 Vienna, Austria
[2] Vet Univ Vienna, Lab Trop Vet Med, A-1210 Vienna, Austria
关键词
D O I
10.1186/1743-422X-5-107
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Human rhinoviruses (HRVs) are the predominant cause of common cold. In addition, HRVs are implicated in the worsening of COPD and asthma, as well as the loss of lung transplants. Despite significant efforts, no anti-viral agent is approved for the prevention or treatment of HRV-infection. Results: In this study we demonstrate that Iota-Carrageenan, a sulphated polysaccharide derived from red seaweed, is a potent anti-rhinoviral substance in-vitro. Iota-Carrageenan reduces HRV growth and inhibits the virus induced cythopathic effect of infected HeLa cells. In addition, Iota-Carrageenan effectively prevents the replication of HRV1A, HRV2, HRV8, HRV14, HRV16, HRV83 and HRV84 in primary human nasal epithelial cells in culture. The data suggest that Iota-Carrageenan acts primarily by preventing the binding or the entry of virions into the cells. Conclusion: Since HRV infections predominately occur in the nasal cavity and the upper respiratory tract, a targeted treatment with a product containing Iota-Carrageenan is conceivable. Clinical trials are needed to determine whether Iota-Carrageenan-based products are effective in the treatment or prophylaxis of HRV infections.
引用
收藏
页数:13
相关论文
共 33 条
[11]   The cold case: Are rhinoviruses perfectly adapted pathogens? [J].
Dreschers, S. ;
Dumitru, C. A. ;
Adams, C. ;
Gulbins, E. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (02) :181-191
[12]   Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein [J].
Este, JA ;
Schols, D ;
DeVreese, K ;
VanLaethem, K ;
Vandamme, AM ;
Desmyter, J ;
DeClercq, E .
MOLECULAR PHARMACOLOGY, 1997, 52 (01) :98-104
[13]   Carrageenan/MIV-150 (PC-815), a combination microbicide [J].
Fernandez-Romero, Jose A. ;
Thorn, Mitchell ;
Turville, Stuart G. ;
Titchen, Kanani ;
Sudol, Kristin ;
Li, Jifan ;
Miller, Todd ;
Robbiani, Melissa ;
Maguire, Robin A. ;
Buckheit, Robert W. ;
Hartman, Tracy L. ;
Phillips, David M. .
SEXUALLY TRANSMITTED DISEASES, 2007, 34 (01) :9-14
[14]   ANTIVIRAL ACTIVITY OF CARRAGEENAN ON HEPATITIS-A VIRUS-REPLICATION IN CELL-CULTURE [J].
GIROND, S ;
CRANCE, JM ;
VANCUYCKGANDRE, H ;
RENAUDET, J ;
DELOINCE, R .
RESEARCH IN VIROLOGY, 1991, 142 (04) :261-270
[15]   POLYSACCHARIDES AS ANTIVIRAL AGENTS - ANTIVIRAL ACTIVITY OF CARRAGEENAN [J].
GONZALEZ, ME ;
ALARCON, B ;
CARRASCO, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) :1388-1393
[16]   Combined antiviral-antimediator treatment for the common cold [J].
Gwaltney, JM ;
Winther, B ;
Patrie, JT ;
Hendley, JO .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) :147-154
[17]   INHIBITION BY IOTA-CARRAGEENAN OF THE SPREAD OF MURINE CYTOMEGALOVIRUS FROM THE PERITONEAL-CAVITY TO THE BLOOD-PLASMA [J].
HAMASUNA, R ;
EIZURU, Y ;
MINAMISHIMA, Y .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :111-116
[18]   PREVENTION OF NATURAL COLDS BY CONTACT PROPHYLAXIS WITH INTRANASAL INTERFERON-ALPHA-2 [J].
HAYDEN, FG ;
ALBRECHT, JK ;
KAISER, DL ;
GWALTNEY, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (02) :71-75
[19]   Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers [J].
Hayden, FG ;
Turner, RB ;
Gwaltney, JM ;
Chi-Burris, K ;
Gersten, M ;
Hsyu, P ;
Patick, AK ;
Smith, GJ ;
Zalman, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3907-3916
[20]   Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials [J].
Hayden, FG ;
Herrington, DT ;
Coats, TL ;
Kim, K ;
Cooper, EC ;
Villano, SA ;
Liu, SY ;
Hudson, S ;
Pevear, DC ;
Collett, M ;
McKinlay, M .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1523-1532